I have low serum cholesterol but a high coronary calcium score, and I was told to take magnesium supplements to bring my ...

The decision to move into phase 3 testing follows the completion of various phase 1 studies that backed the drug's safety, tolerability, and pharmacokinetics, according to Roche.

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to ...